Zobrazeno 1 - 10
of 16
pro vyhledávání: '"John Scholler"'
Autor:
John Scholler, Dana L Schalk, Lawrence G. Lum, Archana Thakur, Edwin T. Bliemeister, Ewa Kubicka, Carl H. June
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Adoptive T cell therapies for solid tumors is challenging. We generated metabolically enhanced co-activated-T cells by transducing intracellular co-stimulatory (41BB, ICOS or ICOS-27) and CD3ζ T cell receptor signaling domains followed by arming wit
Autor:
Mark H. O'Hara, Chong Xu, Adham S. Bear, Benjamin A. Garcia, Robert H. Vonderheide, Beatriz M. Carreno, Khatuna Gabunia, Christina Costeas, John Scholler, Avery D. Posey, Michael J. Ford, Sarah McCuaig, Tatiana Blanchard, Smole Anze, Gerald P. Linette, Daniel J. Powell, Miren L. Baroja, Joseph Cesare, Lee P. Richman
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Activating RAS missense mutations are among the most prevalent genomic alterations observed in human cancers and drive oncogenesis in the three most lethal tumor types. Emerging evidence suggests mutant KRAS (mKRAS) may be targeted immunologically, b
Autor:
Tong Da, Elizabeth L. Buza, John Scholler, Carl H. June, Caroline Sands, Yangbing Zhao, Joseph A. Fraietta, Kathleen Graham, Mauro Castellarin
Publikováno v:
JCI Insight
Off-tumor targeting of human antigens is difficult to predict in preclinical animal studies and can lead to serious adverse effects in patients. To address this, we developed a mouse model with stable and tunable human Her2 (hHer2) expression on norm
Publikováno v:
J Cancer Res Clin Oncol
PURPOSE: Although adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells has shown durable clinical efficacy in patients with CD19(+) B-cell malignancies, the application of this approach to solid tumors is challenging. The goa
Autor:
Brian Keith, Yangbing Zhao, John Scholler, Carl H. June, Regina M. Young, Biliang Hu, Jiangtao Ren, Yanping Luo
Publikováno v:
Cell reports
Cell Reports, Vol 20, Iss 13, Pp 3025-3033 (2017)
Cell Reports, Vol 20, Iss 13, Pp 3025-3033 (2017)
SUMMARY The effects of transgenically encoded human and mouse IL-18 on T cell proliferation and its application in boosting chimeric antigen receptor (CAR) T cells are presented. Robust enhancement of proliferation of IL-18-secreting human T cells oc
Autor:
Vania Aikawa, Christopher A. Hunter, Miroslaw Kozlowski, Jennifer J.D. Morrissette, Michael Klichinsky, David L. Porter, Farzana Nazimuddin, David M. Barrett, John Scholler, David A. Christian, J. Joseph Melenhorst, Michael Kalos, Saar Gill, Stephan A. Grupp, Saad S. Kenderian, Carl H. June, Marco Ruella, Olga Shestova, Simon F. Lacey, Jessica Perazzelli, Ted J. Hofmann
Publikováno v:
Journal of Clinical Investigation. 126:3814-3826
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative rel
Autor:
Prachi R. Patel, Megan M. Davis, Joseph A. Fraietta, David M. Barrett, Simon F. Lacey, John Scholler, John Leferovich, Selene Nunez-Cruz, Stephan A. Grupp, Felipe Bedoya, J. Joseph Melenhorst, Michael C. Milone, Saba Ghassemi, Bruce L. Levine, Roddy S. O’Connor, Stefan Lundh, Changfeng Zhang, Carl H. June
Publikováno v:
Cancer Immunol Res
The success of chimeric antigen receptor (CAR)–mediated immunotherapy in acute lymphoblastic leukemia (ALL) highlights the potential of T-cell therapies with directed cytotoxicity against specific tumor antigens. The efficacy of CAR T-cell therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11fa33a7eb338dcda0c64f8c10178580
https://europepmc.org/articles/PMC8274631/
https://europepmc.org/articles/PMC8274631/
Autor:
Akseli Hemminki, Mikko Siurala, Sonia Guedan, Marco Ruella, Regina M. Young, Brian Keith, Boris Engels, Riikka Havunen, Keisuke Watanabe, John Scholler, Siri Tähtinen, Suvi Sorsa, Tong Da, Carl H. June, Yanping Luo
Publikováno v:
JCI Insight. 3
Pancreatic ductal adenocarcinoma (PDA) is characterized by its highly immunosuppressive tumor microenvironment (TME) that limits T cell infiltration and induces T cell hypofunction. Mesothelin-redirected chimeric antigen receptor T cell (meso-CAR T c
Autor:
Christopher L. Nobles, David M. Barrett, Regina M. Young, Carl H. June, David E Ambrose, Stephan A. Grupp, Bruce L. Levine, Prachi R. Patel, Jun Xu, Hans Bitter, Frederic D. Bushman, Irina Kulikovskaya, Farzana Nazimuddin, Olga Shestova, Simon F. Lacey, Joseph A. Fraietta, Shannon L. Maude, J. Joseph Melenhorst, Vijay Bhoj, Tyler J. Reich, Michael Klichinsky, Terry J. Fry, John Scholler, Saar Gill, Marco Ruella, Elena Orlando
Publikováno v:
Nature medicine. 24(10)
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19(-) leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufac
Autor:
Shannon E. McGettigan, Prachi R. Patel, J. Joseph Melenhorst, Victoria Casado-Medrano, Regina M. Young, Anna Wing, Sonia Guedan, Tong Da, John Scholler, Simon F. Lacey, Carl H. June, Carolyn E. Shaw, Omkar U. Kawalekar, Mireia Uribe-Herranz, Avery D. Posey, Decheng Song, Brian Keith
Publikováno v:
JCI Insight. 3
Successful tumor eradication by chimeric antigen receptor–expressing (CAR-expressing) T lymphocytes depends on CAR T cell persistence and effector function. We hypothesized that CD4+ and CD8+ T cells may exhibit distinct persistence and effector ph